The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno–based regimens.
 
David Moura
Honoraria - Tecnofarma
Research Funding - Cogent Medicine (Inst); PharmaMar (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Bayer; Biosplice; Pfizer; PharmaMar
 
Jose Mondaza-Hernandez
No Relationships to Disclose
 
Alexandra Shirikova
No Relationships to Disclose
 
Pablo Romero-Gonzalez
No Relationships to Disclose
 
Maria Carrera
No Relationships to Disclose
 
Celeste Rodriguez
No Relationships to Disclose
 
Javier Martínez-Trufero
No Relationships to Disclose
 
Ana Sebio
Honoraria - Deciphera; SpringWorks Therapeutics
Consulting or Advisory Role - Deciphera; SpringWorks Therapeutics
Travel, Accommodations, Expenses - Merck
 
Josefina Cruz Jurado
Consulting or Advisory Role - AstraZeneca; Bayer; DAICHII; Deciphera; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar; Roche; seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; deciphera; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche
Travel, Accommodations, Expenses - AstraZeneca; DAICHII; Gilead Sciences; Lilly; Novartis; PharmaMar; Pierre Fabre
 
Claudia Valverde
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Deciphera; Lilly; Mundipharma; PharmaMar
Research Funding - Adaptimmune (Inst); ADC Therapeutics (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; PharmaMar
 
Roberto Diaz Beveridge
No Relationships to Disclose
 
Irene Carrasco-Garcia
Honoraria - Deciphera; Deciphera; PharmaMar
Consulting or Advisory Role - Deciphera; Gedeon Richter
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune (Inst); Cogent Medicine (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); iOmx therapeutics (Inst); Ipsen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Pfizer (Inst); PharmaMar (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Deciphera; PharmaMar
 
Enrique Gonzalez-Billalabeitia
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen Oncology; Pfizer
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Pfizer; Roche; Sanofi
 
Javier Fernandez-Jara
No Relationships to Disclose
 
Carlos Lopez-Jimenez
Travel, Accommodations, Expenses - Deciphera; PharmaMar
 
Nadia Hindi
Honoraria - Deciphera; PharmaMar
Consulting or Advisory Role - Deciphera; PharmaMar
Research Funding - Abbisko Therapeutics (Inst); Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Cogent Biosciences (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim Spain; Deciphera; PharmaMar
 
Antonio Gutierrez
Consulting or Advisory Role - Abbvie; AstraZeneca Spain; Incyte; Janssen; Takeda
Speakers' Bureau - Abbvie; AstraZeneca Spain; Janssen; Takeda
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; Cogent Medicine; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar